ChiCTR2000039570 版本V1.5 版本创建时间2021/02/06 22:59:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000039570 

最近更新日期:

Date of Last Refreshed on:

2021-02-06 22:58:51 

注册时间:

Date of Registration:

2020-10-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

低阿片静脉全麻方案在老年肠道手术中的效果评价

Public title:

Evaluation of the effect of low opioid intravenous general anesthesia program in elderly bowel surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

低阿片静脉全麻方案在老年肠道手术中的效果评价

Scientific title:

Evaluation of the effect of low opioid intravenous general anesthesia program in elderly bowel surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨茜 

研究负责人:

魏珂 

Applicant:

Qian Yang 

Study leader:

Ke Wei 

申请注册联系人电话:

Applicant telephone:

+86 18375752719

研究负责人电话:

Study leader's
telephone:

+86 15902360621

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Zoeee_young@163.com

研究负责人电子邮件:

Study leader's E-mail:

wk202448@hospital-cqmu.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区袁家岗友谊路1号

研究负责人通讯地址:

重庆市渝中区袁家岗友谊路1号

Applicant address:

1 Youyi Road, Yuzhong District, Chongqing, China

Study leader's address:

1 Youyi Road, Yuzhong District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020-585

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-10-14 00:00:00

伦理委员会联系人:

罗天友

Contact Name of the ethic committee:

Luo Tianyou

伦理委员会联系地址:

重庆医科大学附属第一医院

Contact Address of the ethic committee:

The First Affiliated Hospital of Chongqing Medical University

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第一医院麻醉科

Primary sponsor:

Department of Anesthesia, the First Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区袁家岗友谊路1号

Primary sponsor's address:

1 Youyi Road, Yuzhong District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

渝中区

Country:

China

Province:

Chongqing

City:

Yuzhong District

单位(医院):

重庆医科大学附属第一医院

具体地址:

渝中区友谊路1号

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

1 Youyi Road, Yuzhong District

经费或物资来源:

重庆市科卫联合项目

Source(s) of funding:

Chongqing Science and Health Joint Project

研究疾病:

肠道疾病  

Target disease:

Intestinal disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究右美托咪定和利多卡因辅助静脉全麻方案对促进老年患者肠道术后恢复的安全性和有效性。探讨减少阿片药物依赖和应激反应与术后恢复的相关性,为老年患者肠道手术ERAS方案的完善提供参考。  

Objectives of Study:

To explore the safety and effectiveness of dexmedetomidine and lidocaine-assisted intravenous general anesthesia in promoting the recovery of elderly patients after bowel surgery. To explore the relationship between reducing opioid dependence and stress response and postoperative recovery, and to provide references for the improvement of the ERAS program of intestinal surgery for elderly patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

择期行腹腔镜结直肠手术的老年患者,年龄≥65岁,性别不限。

Inclusion criteria

Elderly patients undergoing elective laparoscopic colorectal surgery, aged >= 65 years, regardless of gender.

排除标准:

(1)既往慢性疼痛或长期使用镇痛药物病史;
(2)各类心脏传导阻滞病史;
(3)肝肾功能严重障碍者;
(4)各类镇痛药物过敏病史;
(5)手术原因造成患者循环和呼吸出现衰竭或严重变化,术后需ICU支持治疗。

Exclusion criteria:

(1) Past chronic pain or long-term use of analgesics;
(2) History of various types of heart block;
(3) Those with severe liver and kidney dysfunction;
(4) History of allergy to various analgesic drugs;
(5) The operation causes failure or severe changes in the patients circulation and breathing, and ICU supportive treatment is required after surgery.

研究实施时间:

Study execute time:

From 2020-10-19 00:00:00 To 2021-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-19 00:00:00 To 2021-06-30 00:00:00

干预措施:

Interventions:

组别:

右美托咪定组

样本量:

30

Group:

Dexmedetomidine group

Sample size:

干预措施:

1.诱导前10min内静脉输注右美托咪定0.4μg/kg;2.术中持续泵注右美托咪定0.5μg/kg/h直至手术结束

干预措施代码:

Intervention:

1. Intravenous infusion of dexmedetomidine 0.4μg/kg within 10 minutes before induction; 2. Continuous pumping of dexmedetomidine 0.5μg/kg/h during the operation until the end of the operation

Intervention code:

组别:

利多卡因组

样本量:

30

Group:

Lidocaine group

Sample size:

干预措施:

1.诱导前10min内静脉输注利多卡因1mg/kg;2.术中持续泵注利多卡因2mg/kg/h至手术结束

干预措施代码:

Intervention:

1. Inject lidocaine 1 mg/kg intravenously within 10 minutes before induction; 2. Inject lidocaine 2 mg/kg/h continuously during the operation until the end of the operation

Intervention code:

组别:

生理盐水组

样本量:

30

Group:

Control group

Sample size:

干预措施:

1.诱导前10min内静脉输注生理盐水20ml;2.术中持续泵注生理盐水0.2mlg/kg/h至手术结束

干预措施代码:

Intervention:

1. Inject 20ml of saline intravenously within 10 minutes before induction; 2. Inject 0.2mlg/kg/h of saline continuously during the operation until the end of the operation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

渝中区 

Country:

China

Province:

Chongqing

City:

Yuzhong District

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后肠道功能恢复情况

指标类型:

主要指标

Outcome:

Postoperative bowel function recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清中去甲肾上腺、肾上腺素、ACTH、皮质醇浓度

指标类型:

主要指标

Outcome:

Concentrations of norepinephrine, epinephrine, ACTH, and cortisol in serum

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中及术后镇痛药物的使用量

指标类型:

主要指标

Outcome:

The amount of analgesic drugs used during and after surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age - years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究设计者采用随机数字表法进行分组

Randomization Procedure (please state who generates the random number sequence and by what method):

The research designer uses the random number table method to group

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲

Blinding:

Double blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开 请说明原始数据共享的方式

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the trial complete

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

2023年6月;中国临床实验注册中心; http://www.chictr.org.cn/edit.aspx?pid=28637&htm=4

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

In June 2023; China clinical trials registry http://www.chictr.org.cn/edit.aspx?pid=28637&htm=4

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-10-31 05:45:08